Mandate

Vinge advises EQT IX in connection with the acquisition of Parexel

December 14, 2021 EU, Competition and Regulatory

Vinge has advised EQT IX on the merger control aspects of EQT IX’s and Goldman Sachs Asset Management’s acquisition of Parexel from Pamplona Capital Management for USD 8.5 billion.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. The acquisition was notified to a number of competition authorities worldwide including to the European Commission. Vinge’s team consisted primarily of Emma Johansson, Johan Wahlbom, Victoria Fredén and Jesper Ekman.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026